Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
From Specialist to Proficient Picture taker: Individual Triumphs- Multi-million-euro win in Spanish lottery in doubt due to oversight
- Norovirus is spreading earlier again this year, wastewater data shows
- Boeing's troubled capsule won't carry astronauts on next space station flight
- Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
- Zelensky names spy chief to head presidential office after corruption row
- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- Anthony Joshua's driver charged over Nigeria crash that killed two
